SCHEMBL175435

SCHEMBL175435

COc1ccc(F)c(C)c1C(=O)Oc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
RAB9A P51151 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HPGD P15428 3/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 2/20 0.40
XBP1 P17861 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11908685 0.88 POLB (0.47) MAPTRAB9ANPSR1HPGDALOX15
SCHEMBL14125011 0.83 HPGD (0.45) MAPTRAB9ANPSR1HPGDALOX15
SCHEMBL9283161 0.83 NSD2 (0.41) MAPTRAB9ANPSR1HPGDNPC1
SCHEMBL24926991 0.82 MAPT (0.46) MAPTNPC1CA9ALDH1A1L3MBTL1
SCHEMBL113401 0.82 HSD17B10 (0.51) MAPTRAB9ANPSR1HPGDALOX15
SCHEMBL13397981 0.82 ALDH1A1 (0.39) MAPTRAB9ANPSR1HPGDCA12
SCHEMBL1534095 0.82 MAOB (0.41) MAPTRAB9ANPSR1HPGDALOX15
SCHEMBL1534112 0.82 ALPL (0.47) MAPTRAB9ANPSR1HPGDHSD17B10
SCHEMBL13397730 0.81 ELANE (0.40) MAPTRAB9ANPSR1HPGDALOX15
SCHEMBL9282871 0.81 POLB (0.39) MAPTRAB9ANPSR1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122651-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2023-04-20 US disclosed
CN-115448849-B Preparation method of 2-benzyloxy-3-dibenzylamino-5-fluoro-6-methylbenzoic acid phenyl ester 苏州富士莱医药股份有限公司 2023-02-03 CN disclosed
CN-115448849-A Preparation method of 2-benzyloxy-3-dibenzylamino-5-fluoro-6-methyl benzoate 苏州富士莱医药股份有限公司 2022-12-09 CN disclosed
US-20210122709-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2021-04-29 US disclosed
US-20200055813-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2020-02-20 US disclosed
US-20190077803-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2019-03-14 US disclosed
US-20190002398-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2019-01-03 US disclosed
EP-2424834-B1 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF HARVARD COLLEGE (US) 2018-07-11 EP disclosed
EP-2424834-B1 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF HARVARD COLLEGE (US) 2018-07-11 EP disclosed
EP-3000805-B1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-10-18 EP disclosed
US-20130109657-A1 C7-Fluoro Substituted Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2013-05-02 US disclosed
US-20120302527-A1 C7-Fluoro Substituted Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2012-11-29 US disclosed
US-20120135968-A1 Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-31 US disclosed
US-20120115818-A1 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) 2012-05-10 US disclosed
US-20120115818-A1 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) 2012-05-10 US disclosed
EP-2424834-A2 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO President and Fellows of Harvard College (US) 2012-03-07 EP disclosed
WO-2012021712-A1 TETRACYCLINE ANALOGS TETRAPHASE PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
WO-2010126607-A2 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-11-04 WO disclosed
US-20100105671-A1 C7-fluoro substituted tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. 2010-04-29 US disclosed
US-20100105671-A1 C7-fluoro substituted tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115818-A1 SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO TET1, TET3, TYMS MAPT 2105/4885RAB9A 2715/4885NPSR1 4730/4885
US-20200055813-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885
US-20100105671-A1 C7-fluoro substituted tetracycline compounds F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885
US-20120302527-A1 C7-Fluoro Substituted Tetracycline Compounds F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885
US-20190002398-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885
US-20230122651-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885
US-20120135968-A1 Tetracycline Compounds TUBB, TUBA1C, TUBA1A MAPT 103/4885RAB9A 1953/4885NPSR1 4283/4885
US-20190077803-A1 TETRACYCLINE COMPOUNDS TUBB, TUBA1C, TUBA1A MAPT 103/4885RAB9A 1953/4885NPSR1 4283/4885
US-20130109657-A1 C7-Fluoro Substituted Tetracycline Compounds F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885
US-20210122709-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A MAPT 422/4885RAB9A 407/4885NPSR1 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.